Literature DB >> 12221109

A conditional mutation affecting localization of the Menkes disease copper ATPase. Suppression by copper supplementation.

Byung-Eun Kim1, Kathryn Smith, Carisa K Meagher, Michael J Petris.   

Abstract

Copper is an essential co-factor for several key metabolic processes. This requirement in humans is underscored by Menkes disease, an X-linked copper deficiency disorder caused by mutations in the copper transporting P-type ATPase, MNK. MNK is located in the trans-Golgi network where it transports copper to secreted cuproenzymes. Increases in copper concentration stimulate the trafficking of MNK to the plasma membrane where it effluxes copper. In this study, a Menkes disease mutation, G1019D, located in the large cytoplasmic loop of MNK, was characterized in transfected cultured cells. In copper-limiting conditions the G1019D mutant protein was retained in the endoplasmic reticulum. However, this mislocalization was corrected by the addition of copper to cells via a process that was dependent upon the copper binding sites at the N-terminal region of MNK. Reduced growth temperature and the chemical chaperone, glycerol, were found to correct the mislocalization of the G1019D mutant, suggesting this mutation interferes with protein folding in the secretory pathway. These findings identify G1019D as the first conditional mutation associated with Menkes disease and demonstrate correction of the mislocalized protein by copper supplementation. Our findings provide a molecular framework for understanding how mutations that affect the proper folding of the MNK transporter in Menkes patients may be responsive to parenteral copper therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12221109     DOI: 10.1074/jbc.M208737200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy.

Authors:  Marina L Kennerson; Garth A Nicholson; Stephen G Kaler; Bartosz Kowalski; Julian F B Mercer; Jingrong Tang; Roxana M Llanos; Shannon Chu; Reinaldo I Takata; Carlos E Speck-Martins; Jonathan Baets; Leonardo Almeida-Souza; Dirk Fischer; Vincent Timmerman; Philip E Taylor; Steven S Scherer; Toby A Ferguson; Thomas D Bird; Peter De Jonghe; Shawna M E Feely; Michael E Shy; James Y Garbern
Journal:  Am J Hum Genet       Date:  2010-02-18       Impact factor: 11.025

2.  Mutations associated with Charcot-Marie-Tooth disease cause SIMPLE protein mislocalization and degradation by the proteasome and aggresome-autophagy pathways.

Authors:  Samuel M Lee; James A Olzmann; Lih-Shen Chin; Lian Li
Journal:  J Cell Sci       Date:  2011-09-06       Impact factor: 5.285

Review 3.  Molecular basis of neurodegeneration and neurodevelopmental defects in Menkes disease.

Authors:  Stephanie Zlatic; Heather Skye Comstra; Avanti Gokhale; Michael J Petris; Victor Faundez
Journal:  Neurobiol Dis       Date:  2015-01-10       Impact factor: 5.996

Review 4.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

Review 5.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  In Vivo Modeling of the Pathogenic Effect of Copper Transporter Mutations That Cause Menkes and Wilson Diseases, Motor Neuropathy, and Susceptibility to Alzheimer's Disease.

Authors:  Stephen W Mercer; Jianbin Wang; Richard Burke
Journal:  J Biol Chem       Date:  2017-01-24       Impact factor: 5.157

Review 7.  Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes.

Authors:  P de Bie; P Muller; C Wijmenga; L W J Klomp
Journal:  J Med Genet       Date:  2007-08-23       Impact factor: 6.318

8.  Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R.

Authors:  Jingrong Tang; Anthony Donsante; Vishal Desai; Nicholas Patronas; Stephen G Kaler
Journal:  Mol Genet Metab       Date:  2008-08-26       Impact factor: 4.797

Review 9.  Rescue of folding defects in ABC transporters using pharmacological chaperones.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

10.  The copper-transporting capacity of ATP7A mutants associated with Menkes disease is ameliorated by COMMD1 as a result of improved protein expression.

Authors:  Willianne I M Vonk; Prim de Bie; Catharina G K Wichers; Peter V E van den Berghe; Rozemarijn van der Plaats; Ruud Berger; Cisca Wijmenga; Leo W J Klomp; Bart van de Sluis
Journal:  Cell Mol Life Sci       Date:  2011-06-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.